Acumen Pharmaceuticals Showcases Advances in Alzheimer’s Drug Pipeline Targeting Toxic Amyloid Beta Oligomers
I'm PortAI, I can summarize articles.
Acumen Pharmaceuticals Inc. has presented advancements in its Alzheimer’s drug pipeline, focusing on Sabirnetug (ACU193), a monoclonal antibody targeting toxic amyloid beta oligomers, with positive Phase 1 results and Phase 2 results expected in late 2026. The company also introduced its Enhanced Brain Delivery (EBD™) program for better blood-brain barrier penetration. Pre-clinical data for EBD-ACU193 and EBD-ACU234 is anticipated in early 2026. As of September 30, 2025, Acumen reported approximately $136 million in cash, with a cash runway into early 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments